Obstetrics & gynecology science

Korean Society of Obstetrics and Gynecology (대한산부인과학회)
권호 표지

Current opinion of the treatment of female voiding dysfunction

여성 배뇨장애 치료의 최신 지견

Jeon, Myung-Jae;Bai, Sang-Wook;Kim, Sei-Kwang
전명재;배상욱;김세광

  • Published : 2008.03.15
⟨ Previous Next ⟩

Abstract

노년 인구의 증가에 따른 여성 배뇨장애의 발생빈도 증가로 인하여 이에 대한 관심이 점차 높아지고 있다. 최근 복압성 요실금, 과민성 방광, 배뇨곤란의 처치에 있어 다양한 치료적 접근이 시도되고 있다. 복압성 요실금에 대해서는 수술적 치료, 과민성 방광에 대해서는 약물 치료와 방광 훈련, 배뇨곤란 치료를 위해서는 간헐적 자가 도뇨가 현재까지는 치료의 중심을 이루고 있다. 그러나, 이러한 표준 치료방법들이 모든 환자에게 다 적용될 수는 없으며 항상 성공적인 결과로 이어지지는 않기 때문에, 부인과 의사들은 선택 가능한 여러 치료방법들에 대해서도 지식을 갖추고 있을 필요성이 있다. 본 논문에서는 문헌적 근거에 기초하여 현재 이들 질환 치료에 사용되고 있는 보존적, 약물 및 수술적 치료법들의 치료효과에 대해 재평가하고, 복압성 요실금 치료를 위한 최신 수술기법, botulinum toxin A 주입술, 천수 신경조절술, 후경골 신경자극술, 방사주파 치료, 신약 등 과민성 방광 및 배뇨곤란에 사용 가능한 최근의 치료법들에 대해 알아보고자 한다.

Keywords

References

  1. Wilson D. Outcomes of conservative treatment. In: Cardozo C, Staskin D, editors. Texrbook of female urology and urogynecology. Abingdon: Informa Healthcare; 2007. p.407-28.
  2. Richardson DA. Conservative management of urinary incontinence: a symposium. J Reprod Med 1993; 38: 659-61.
  3. Song C, Park JT, Heo KO, Lee KS, Choo MS. Effects of bladder training and/or tolterodine in female patients with overactive bladder synd¬rome: a prospective, randomized study. J Korean Med Sci 2006; 21: 1060-3. https://doi.org/10.3346/jkms.2006.21.6.1060
  4. Laipes J, Diokno C, Silber SJ, Lowe B.S. Clean, intermittent se1f-catheterizatio in the treatment of lower urinary tract disease. J Urol 1972; 107: 458-61. https://doi.org/10.1016/S0022-5347(17)61055-3
  5. Wyndaele J, Maes D. Clean intermittent se1f¬catheterization: a 12 year fullowup. J Urol 1990; 143: 906-8. https://doi.org/10.1016/S0022-5347(17)40132-7
  6. Andersson KE, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J. Pharmacological treatment of urinary incontinence In: Abtams P, Cardozo L, Khoury S, Wein A, editors., 3rd International Corsulrarion on Incontinence. Paris: Health Publication Ltd.; 2005. p.809- 54.
  7. Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol 2007; 52: 531-8. https://doi.org/10.1016/j.eururo.2006.11.016
  8. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifephase. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 512-9. https://doi.org/10.1007/s00192-005-0058-6
  9. Chapple C, Steers W, Notron P, Millard R, Kralidis G, Glavind K, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and sefety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of ovetactive bladder. BJU Int 2005; 95: 993-1001. https://doi.org/10.1111/j.1464-410X.2005.05454.x
  10. Stahl MM, Ekstrom B, Sparf B, Mattiasson A, Andesson KE. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of dettusor overactivity. Neurouml. Urodyn 1995; 14: 647-55. https://doi.org/10.1002/nau.1930140606
  11. Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian pati¬ents with symptoms of overactive bladder. Int J Urol 2002; 9: 247-52. https://doi.org/10.1046/j.1442-2042.2002.00460.x
  12. Rudy D, Cline K, Harris. R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-80. https://doi.org/10.1016/j.urology.2005.08.017
  13. Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-besed, randomized, study. BJU Int. 2007; 99: 836-44. https://doi.org/10.1111/j.1464-410X.2006.06658.x
  14. Kaplan SA, Roehrborn CG, Dmochowsik R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006; 68: 328-32. https://doi.org/10.1016/j.urology.2006.03.006
  15. Hilton P, Hertogs K, Stanton SL. The use of desmopressin(DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983; 46: 854-5. https://doi.org/10.1136/jnnp.46.9.854
  16. Robinson D, Cardozo L, Akeson M, Hvistendahi G, Riis A, Norgaard JP. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 2004; 93: 996-1000. https://doi.org/10.1111/j.1464-410X.2004.04768.x
  17. Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder, BJU Int 2007; 100: 337-45. https://doi.org/10.1111/j.1464-410X.2007.06980.x
  18. Badawi JK, Langbein S. Selective beta¬-adrenoreceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence. Pharmazie 2006; 61: 175-8.
  19. Carbone A, Palleschi G, Conte A, Bova G, Iacovelli E, Bettolo RM, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006; 29: 206-14. https://doi.org/10.1097/01.WNF.0000228174.08885.AB
  20. Millard RJ, Moore K, Reneken R, Yalcin I, Bump RC, Duloxetine UI Study Group. Dul¬oxetine versus placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial, BJU Int 2004; 93: 311-8. https://doi.org/10.1111/j.1464-410X.2004.04607.x
  21. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004; 114: 511-9. https://doi.org/10.1097/AOG.0b013e3181b1377b
  22. Duckett JR, Aggatwal I, Patil A. Duloxetine treatment for women awaiting continence surgery. Int Urogynecol J Pelvic Floor Dyfunct 2006; 17: 563-5. https://doi.org/10.1007/s00192-005-0063-9
  23. Kumar A, Mandhani A, Gogoi S, Srivastava A. Management of functional bladder neck obstruction in women: use of alpha- blockers and paediatric for bladder incision. J Urol 1999; 162: 2061-5. https://doi.org/10.1016/S0022-5347(05)68101-3
  24. Farrell SA, Webster RD, Higgins LM, Steeves RA. Duration of postoperative catheterization: A randomized, double-blind trial comparing two catheter manegement protocols and the effect of bethanechol chloride. Int Urogynecol J Pelvic Floor Dysfunct 1990; 1: 132-5. https://doi.org/10.1007/BF00376597
  25. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia, ALGEBI Study Group. Eur Urol 1997; 31: 190-8. https://doi.org/10.1159/000474449
  26. Wilde MI, McTavish D. Tamsulosin. A review of its pharomrological properties and therapeutic potential in the mangement of symptomatic benign prostatic hyperplasia, Dregs 1996; 52: 883-98. https://doi.org/10.2165/00003495-199652060-00012
  27. Stanton SL. Drug management of voiding difficulties in the female. In: Cardozo L, editor. Update on Drugs and Lower Urinary Tract. London: Royal Society of Medicine; 1988. p.21-4.
  28. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentenet M, et al. Experience with 100 cases treated with botul¬inum: a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refrac¬tory to anticholinergics. J Urol 2006; 176: 177-85. https://doi.org/10.1016/S0022-5347(06)00590-8
  29. Karseney G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006; 68: 1193-7. https://doi.org/10.1016/j.urology.2006.08.1069
  30. Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 2006; 13: 3291-5.
  31. Ruffion A, Capelle O, Paperel P, Leriche B, Leridie A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006; 97: 1030-4. https://doi.org/10.1111/j.1464-410X.2006.06091.x
  32. Phelan MW, Franks M, Somogyi GT, Yokoynma T, Fraser MO, Lavelle JP, et al., Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfuncion. J Urol 2001; 165: 1107-10. https://doi.org/10.1016/S0022-5347(05)66438-5
  33. Kuo HC. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003; 61, 550-4. https://doi.org/10.1016/S0090-4295(02)02541-4
  34. Smith CP, O'Leary M, Erickson J, Somogyi GT, Chancellor MB. Botulinum toxin urethral sphineter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic, Floor Dysfunct 2002; 13: 185-6. https://doi.org/10.1007/s192-002-8350-6
  35. Leach GE, Dmochowski RR, Appell RA, Blaivas JG, Hadley HR, Luber KM, et al. Female stress urinary incontinence clinical guidelines panel summary report on surgical management of female stress urinary incontinence. J Urol 1997; 158: 875-80. https://doi.org/10.1016/S0022-5347(01)64346-5
  36. Nilsson CG, Falconer C, Rezapour M. Seven-year follow-up of tho tension-free vaginal tape proce¬dure for treatment of urinary incontinence. Obstet Gynecol 2004; 104: 1259-62. https://doi.org/10.1097/01.AOG.0000146639.62563.e5
  37. Nilsson CG. Tension-free vaginal tape procedure for the treatment of female urinary stress incontinence. In: Cardozo C. Staskin D, editors. Textbook of female urology and urogynecology. Abi¬ngdon: Informa Healthcare; 2007. p.918-23.
  38. Doo CK, Hong B, chung BJ, Kim JY, Jung HC, Lee KS. et al. Five-year outcomes of the tension-free vaginal tape procedure for treatment of female stress urinary incontinence. Eur Urol 2006; 50: 333-8. https://doi.org/10.1016/j.eururo.2006.04.007
  39. 정여화, 전명재, 정다정, 박주현, 김세광, 김재욱 등. 복압성 요실금 수술시 tension-free vaginal tape의 치료 성적; 요도 괄약근 부전증 환자와 비요도 괄약근 부전증 환자의 비교. 대한산부회지 2007; 50: 345-51.
  40. Lord HE, Taylor JD, Finn JC, Tsokos N, Joffrey JT, Atherton MJ, et al. A randomized controlled equivalence trial of short-trem complications and suprapubic of tension-free vaginal tape and sup¬rapubic urethral support sling for treating stress incontinence. BJU Int 2006; 98: 367-76. https://doi.org/10.1111/j.1464-410X.2006.06333.x
  41. Delorme E, Droupy S, de Tayrac R, Delmas V. Transobturator tape(Uratape): a new minimally invasive procedure to treat female urinary incontinence. Eur Urol. 2004; 45: 203-7. https://doi.org/10.1016/j.eururo.2003.12.001
  42. Winters JC, Fitzgerald MP, Barber MD. The use of synthetic mesh in female pelvic reconstructive surgery, BJU Int 2006; 98: 70-6; discussion 77.
  43. Zahn CM, Siddique S, Hemandez S, Lockrow EG. Anatomic comparison of two transobtruator tape procedures, Obstet Gyncol 2007; 109: 701-6. https://doi.org/10.1097/01.AOG.0000255662.79008.18
  44. Debodance P. Trans-obturator urethral sling for the surgical correction of female stress urinary incontinence: outside-in(Monarc) versus inside-out (TVT-O). Are the two ways reassuring? Eur J Obstet Gynecol Reprod Biol 2007; 133: 232-8. https://doi.org/10.1016/j.ejogrb.2006.05.015
  45. O'Connor R, Nanigian DK, Lyon MB, Ellison LM, Bales GT, Stone AR. Early outcomes of mid-urethral slings for female stress urinary incontinence stratified by valsalva leak point pressure. Neurourl Urodyn 2006; 25: 685-8. https://doi.org/10.1002/nau.20286
  46. Deng DY, Rutman M, Raz S, Rodriguez LV. Presentation and management of major compli¬cations of midurethral slings: are complications under-reported? Neurourol Urodyn 2007; 26: 46-52. https://doi.org/10.1002/nau.20357
  47. Yaog JM, Huang WC, Sonographic findings in a case of voiding dyfuncion secondary to the tension-free vaginal tapt(TVT) procedure. Ultrasound Obstet Gynecol 2004; 23: 302-4. https://doi.org/10.1002/uog.995
  48. Huckabay C, Nitti VW. Diagnosis and treatment of obstruction following incontinence surgery: urethrolysis and other techniques. In: Cardozo C, Staskin D, editors. Textbook of female urology and urogynecology. Abingdon: Informa Healthcare; 2007. p.981-95.
  49. Leng WW, Chancellor MB. How sacral nerve stimulation nuuromodulation works. Urol Clin North Am 2005; 32: 11-8. https://doi.org/10.1016/j.ucl.2004.09.004
  50. Scheepens WA, de Bie RA, Weil EH, van Kerrebroeck PE. Unilateral versus bilateral. sacral neuromodulation in patients with cbronic lower urinary dysfuncion. J Urol 2002; 168: 2046-50. https://doi.org/10.1016/S0022-5347(05)64292-9
  51. Daneshgari F. Electrical stimulation of the lower urinary tract. In: Cerdozo C, Staskin D, editors. Testbook of female urology and urogynecology. Abingdon; Informa Healthcare; 2007. p.127-5¬87.
  52. Steller M, Copeland S, Millard R. The efficacy of acupuncture in reversing the unstable bladder in pig-tailed monkeys [Abstract]. J Urol 1987; 137: 104A .
  53. Klinger H, Pycha A, Schmidbauer J, Marberger M. Use of peripheral neuromodulation for treat¬ment of detrusor overactivity: a urodynamic¬based study. Urology 2000; 56: 766-71. https://doi.org/10.1016/S0090-4295(00)00727-5
  54. Govier FE, Litwiller S, Nitti V, Kreder Jr, Rosenblatt P. Percutaneous afferent neuromodularion for the refractory overactive bladder: results of a multicenter study. J Urol 2001; 165: 1193-8. https://doi.org/10.1016/S0022-5347(05)66469-5
  55. Vandoninck V, van Balken MR, Finazzi Agro E, Heesakkers JP, Debruyne FM, Kiemeney LA, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction; urodynamic data, Neurourol Urodyn 2004; 23: 246-51. https://doi.org/10.1002/nau.10158
  56. Dmochowski RR, Avon M, Ross J, Cooper JM, Kaplan R, Love B, et al. Transvaginal radio frequency treatment of the endopelvic fascia: a prospective evaluation for the treatment of genuine stress urinary incontinence. J Urol 2003; 169: 1028-32. https://doi.org/10.1097/01.ju.0000048686.50716.ef
  57. Lenihan JP. Comparison of the quality of life after nonsurgical radiofrequency energy tissue micro-remodeling in premenopausal and postmenopausal women with moderate-to-severe stress urinary incontinence. Am J Obstet Gynecol 2005; 192: 1995-8; discussion 1999-2001. https://doi.org/10.1016/j.ajog.2005.02.041
  58. Appcll RA, jurna S, Wd], WG, Lenihan JP, Klimberg IW, Kanellos A, et al, Transurethral rndiofrequency energy collagen micro-renxxIeling fur treatJIrnt of stress incontinence. Neurourol Urodyn 2006; 25; 331-6. https://doi.org/10.1002/nau.20185
  59. Appell RA, Singh G, Klimberg IW, Graham C, Juma S, Wells WG, et al. Nonsurgical radio¬freqcency collagen denaturation fo stress urinary incontinence. Expert Rev Med Devices 2007; 4: 455-61. https://doi.org/10.1586/17434440.4.4.455
  60. Winters JC, Chiverton A, Scarpero HM, Prats LJ Jr. Collagen injection therapy in elderly women: long-term results and patient satisfaction. Urology 2000; 55: 856-61. https://doi.org/10.1016/S0090-4295(00)00514-8
  61. Mayer R, Lightfoot M, Jung I. Preliminary evaluation of calcium hydroxyapatite as a transurethral bulking agent for stress urinary incontinence. Urology 2001; 57: 434-8. https://doi.org/10.1016/S0090-4295(00)01098-0
  62. Appell RA, Davila GW. Treatment options for patients with suboptimal response to surgery for stress urinary incontinence. Curt Med Res Opin 2007; 23: 285-92. https://doi.org/10.1185/030079906X162845
  63. Tamanini JT, D'Ancona CA, Netto NR Jr. Treatment of intrinsic sphincter deficiency using the Macroplastique Implantation System: two-year follow-up. J Endourl 2004; 18: 906-11. https://doi.org/10.1089/end.2004.18.906
  64. Cole EE, Scarpero HM, Dmochoeski RR. The artificial urethral spbincter for treatment of stress urinary incontinence in women. In Cardozo C, Staskin D, editors. Textbook of female urology and urogynecology. Abingdon: Infofma Healthcare; 2007. p.961-70.